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Abstract: Cisplatin is one of the most commonly used drugs for the treatment of various solid cancers.
However, its efficacy is restricted by severe side effects, especially dose-limiting nephrotoxicity. New
platinum-based compounds are designed to overcome this limitation. Previous investigations
showed that the platinum(IV)–nitroxyl complex PN149 is highly cytotoxic in various tumor cell lines.
In the present study, investigations with PN149 were extended to normal human kidney tubule
epithelia. Coincident with higher intracellular platinum accumulation, the cytotoxicity of PN149 in
the proximal tubule epithelial cell line ciPTEC was more pronounced compared to the established
platinum chemotherapeutics cisplatin, carboplatin and oxaliplatin. Quantitative gene expression
profiling revealed the induction of ROS-inducible and anti-oxidative genes, suggesting an oxidative
stress response by PN149. However, in contrast to cisplatin, no pro-inflammatory response was
observed. Genes coding for distinct DNA damage response factors and genes related to apoptosis
were up-regulated, indicating the activation of the DNA damage response system and induction of
the apoptotic cascade by PN149. Altogether, a comparable transcriptional response was observed for
PN149 and the platinum chemotherapeutics. However, the lack of inflammatory activity, which is a
possible cause contributing to toxicity in human renal proximal tubule epithelia, might indicate the
reduced nephrotoxic potential of PN149.
Keywords: cisplatin; platinum drugs; DNA damage response; nephrotoxicity; chemotherapeutic
drugs; gene expression profiling
1. Introduction
Cisplatin (Figure 1) is one of the most commonly used drugs in chemotherapy. It
is applied against a variety of cancers such as bladder, lung and ovarian cancer and
carcinomas of the head and neck [1]. Cisplatin is particularly effective in combination
therapy against testicular germ cell tumors, where cure rates of over 80% are achieved [2].
However, its clinical application is restricted by tumor cell resistance, either intrinsic to
the tumor or acquired during cycles of cisplatin therapy, and severe side effects, especially
dose-limiting nephrotoxicity [3]. One-third of patients receiving cisplatin therapy suffer
severe renal toxicity, which is commonly manifested as acute kidney injury (AKI) [4].
The mechanisms of the toxic activity of cisplatin have been thoroughly investigated in
various cancer cell lines [5–8]. Cisplatin enters the cells by both passive diffusion and active
transport mechanisms, mediated by cellular membrane transporters [9,10]. Upon entering
the cells, cisplatin becomes activated by the replacement of the two chloride leaving groups
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by water and subsequently binds covalently to DNA, resulting in various DNA platinum
lesions. DNA platination activates a number of signal transduction pathways that control
cell cycle arrest/DNA repair or apoptosis. Depending on the extent of DNA damage, cell
cycle arrest will be induced to ensure time for the repair of platinum damage, or, in case of
excess damage, platinum lesions will trigger apoptosis, which is thought to be crucial for
cisplatin toxicity and hence therapeutic efficacy in cancer cells, but also for the toxic side
effects in normal cells [8,11]. The mechanisms underlying cisplatin-induced nephrotoxicity
are not fully understood, but besides cisplatin-induced DNA damage response (DDR) and
apoptosis, the generation of reactive oxygen species (ROS) and inflammatory processes
are possible causes contributing to cisplatin toxicity in kidney cells [4,12–16]. Furthermore,
the binding of cisplatin to the intracellular thiol-containing molecule glutathione might
result in the production of a nephrotoxic intermediate that could also contribute to the
dose-restricting toxic side effect [17–19].
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the structure of cisplatin led to the development of nu erous lati logues, which
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and oxaliplatin (Figure 1) have achieved worldwide a proval for chemotherapeutic treat-
ment. Carboplatin is less toxic than cisplatin and shows fewer side effects, with severe
myelosuppression being dose-limiting for therapeutic treatment. However, carboplatin
shows no activity in cisplatin-resistant tumor cells in vitro and is used against essentially
the same tumor types as cisplatin in the clinic. Oxaliplatin, on the other hand, has a
different pattern of sensitivity compared to cisplatin and carboplatin. In numerous clinical
trials, oxaliplatin showed activity in cisplatin-resistant colorectal cancer patients, resulting
in clinical approval for the treatment of advanced colorectal cancer, which is insensitive
towards cisplatin treatment [11,21,22]. With respect to side effects, oxaliplatin treatment
leads to severe neurotoxicity as a dose-limiting side effect [3].
To broaden the spectrum of clinical application to additional tumor types, the search
for cisplatin analogues continues, with new platinum compounds being designed and
tested in pre-clinical and clinical investigations [20,23]. Of particular interest are plat-
inum(IV) complexes, as they might possess sufficient oral bioavailability for oral platinum
chemotherapy [24]. Platinum(IV)–nitroxyl complexes (PNCs) are hybrid compounds com-
bining platinum with biologically active nitroxyl pharmacophores (Figure 1) [25–27]. Due
to the two additional axial ligands, PNCs are highly lipophilic, which allows easy uptake
by cells. We found that PNCs were cytotoxic in tumor cell lines of different origin [28,29].
Furthermore, we observed that PNCs were still active in cisplatin-resistant bladder and
testis tumor cells, indicating that PNCs were able to circumvent the cisplatin resistance
phenotype in vitro [28]. This observation could be highly relevant for potential clinical
use in tumors that are unresponsive to cisplatin treatment. Generally, PNCs share a com-
parable mode of action to that of cisplatin in tumor cells, as demonstrated for the PNC
PN149 [e-ammine-d-(3-amino-2,2,5,5-tetramethylpyrrolidine-1-oxyl)-a,f -bis(butanoato)-b,c-
dichloro-platinum(IV)] in the RT112 bladder cancer cell line and A498 kidney cancer cell
line. However, an inflammatory response was restricted to RT112 cells, but was not ob-
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served in A498 kidney cancer cells [29]. As inflammatory processes have been implicated
with cisplatin-induced nephrotoxicity, the lack of an inflammatory response following
PN149 treatment in kidney cancer cells suggested a less nephrotoxic potential of PN149.
To elucidate the mode of action of PN149 in normal human kidney cells in comparison to
the clinically approved platinum chemotherapeutics cisplatin, carboplatin and oxaliplatin,
gene expression analysis was applied [30]. Selected genes related to transcription factors,
(oxidative) stress response, DNA damage response/repair, cell cycle control and apoptosis
were chosen for the analysis. As a model system for the investigations in kidney cells, the
renal cell line ciPTEC, which is derived from human proximal tubule epithelial cells, was
used [31].
2. Materials and Methods
2.1. Cell Culture
The renal cell line ciPTEC (conditionally immortalized proximal tubule epithelial
cells) [31], which was purchased from Dr. Martijn Wilmer, was used in the current study.
ciPTECs were cultured in DMEM-HAM’s F12 phenol red-free medium (Gibco, Thermo
Fisher Scientific, Dreieich, Germany) supplemented with 10% fetal calf serum (FCS) (Invit-
rogen, Darmstadt, Germany), 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenium,
36 ng/mL hydrocortisone, 10 ng/mL EGF (epidermal growth factor) and 40 pg/mL tri-
iodothyronine (Sigma-Aldrich, Steinheim, Germany). For maintaining the proliferation
status, cells were cultured at 33 ◦C in a humidified atmosphere of 5% CO2 in medium
supplemented with 1% penicillin/streptomycin (P/S) (Sigma-Aldrich, Steinheim, Ger-
many). For the experiments, ciPTECs were seeded at a density of 55,000 cells/cm2 in cell
culture flasks and were cultivated for 24 h at 33 ◦C. After 24 h, cells were transferred to
37 ◦C for maturation, while the medium was refreshed with medium containing no P/S.
Cells were kept at 37 ◦C for 7 days while the medium was replaced every 2–3 days. For
comparative analysis with the data obtained with the permanent cell line ciPTEC, studies
were performed with primary patient-derived renal normal tissue cells (NT), which were
obtained from patients at the University Medical Center Mainz. Cells were isolated from
primary renal cancer samples of patients who underwent nephrectomy at the Department
of Urology, University Medical Center Mainz. The study was performed in agreement
with the Declaration of Helsinki and approved by local ethics committee (No. 837.005.09,
Landesärztekammer Rheinland-Pfalz, Mainz, Germany). Each patient provided informed
consent. NT cells were cultivated in RPMI-1640 medium (Sigma-Aldrich, Steinheim, Ger-
many) containing 10% FCS and 5% P/S at 37 ◦C in a humidified atmosphere of 5% CO2.
2.2. Platinum-Based Compounds
The three clinically approved platinum-based compounds cisplatin, carboplatin and
oxaliplatin and the experimental drug PN149 were used. An infusion solution of cisplatin
with a concentration of 1 g/L was kindly provided by the Clinical Centre Karlsruhe.
Infusion solutions of carboplatin and oxaliplatin were purchased from Accord Healthcare
Limited (Middlesex, UK) with a respective concentration of 10 mg/mL and 5 mg/mL.
PN149 was synthesized at the Institute of Problems of Chemical Physics of the Russian
Academy of Sciences. Incubation times with the platinum compounds were based on the
excretion time of cisplatin in patients. Cisplatin shows a 3 phase kinetic excretion with a
first half-life time (t1/2α) of 14–49 min followed by a second half-life period (t1/2β) of
0.7–4.6 h and a third half-life period (t1/2γ) of 24–127 h [32,33]. To be in line with the
clinical conditions, an incubation time of 24 h was chosen for the experiments, with the
exception of intracellular platinum accumulation studies, which were performed for 2 h.
Concentrations of the compounds were chosen based on the blood plasma levels measured
in patients after drug treatment. The concentration of cisplatin ranged from 10–50 µM.
Due to its slower reaction kinetics compared to cisplatin, the concentration of carboplatin
ranged from 100 to 500 µM, whereas oxaliplatin is clinically used in a similar range to
cisplatin [32,34].
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2.3. Cytotoxicity Studies
Toxicity was determined by relative cell count (RCC). ciPTECs were seeded in dupli-
cates in T25 flasks and cultivated as stated before. After maturation, cells were incubated
for 24 h with cisplatin (10, 20, 50 µM), PN149 (10, 20, 50 µM), carboplatin (100, 200, 500 µM)
or oxaliplatin (20, 50, 100 and 150 µM) followed by a post-cultivation period of 48 h. Cell
count was then determined using a CASY® cell counter (CASY® TTC Cell Counter &
Analyzer System). The cell counts of the treated samples were normalized to the un-
treated control to obtain the RCC expressed as percentage. RCC was determined in three
independent experiments.
2.4. Intracellular Platinum Accumulation
Atomic absorption spectroscopy (AAS) was used to determine the intracellular accu-
mulation after treatment with the platinum compounds. ciPTECs were seeded in T75 flasks
and cultivated as stated before. Matured cells were treated for 2 h with 50 µM of cisplatin,
oxaliplatin or PN149 or 300 µM carboplatin. Cells were then harvested via centrifugation
and total cell count was determined. Afterwards, cell pellets underwent an acidic digestion
using a solution of 30% H2O2 and 65% HNO3 (1:1 (v:v)) (Roth, Karlsruhe, Germany) and
evaporation. The residue was dissolved in 0.2% HNO3 and platinum amount was ana-
lyzed at a wavelength of 26,594 nm in a graphite furnace using a PinAAcle 900 T (Perkin
Elmer, Waltham, MA, USA). Atomization was performed using a furnace temperature
program consisting of two drying steps of 120 ◦C for 30 s and 140 ◦C for 45 s followed by a
pyrolysis step of 1300 ◦C for 20 s, an atomization step of 2400 ◦C for 5 s as well as a heating
step for clean out of 2500 ◦C for 5 s. Intracellular accumulation was determined in three
independent experiments and was calculated as ng Pt/106 cells.
2.5. Gene Expression Profiling by High-Throughput RT-qPCR
Gene expression profiles were generated using a high-throughput RT-qPCR method
previously established in the institute [30]. ciPTECs were cultivated in T25 flasks as stated
before. Matured cells were incubated for 24 h with cisplatin or PN149 (10, 20, 50 µM),
carboplatin (100, 200, 500 µM) or oxaliplatin (20, 50, 100 and 150 µM) and subsequently har-
vested via centrifugation. RNA isolation and generation of gene expression profiles using
a Fluidigm dynamic array on a BioMark™ (Rheinau, Germany) system were performed
as previously described [29]. For comparative analysis of ciPTEC with primary kidney
cells, 5 × 105 NT cells were seeded in 10 cm dishes and cultivated for 24 h. Afterwards,
cells were incubated with 20 µM cisplatin for 24 h followed by harvesting the cells via
centrifugation and generation of gene expression profiles. Gene expression profiles in
ciPTEC were generated in three independent experiments. Due to the limited amount of
tissue material, gene expression analysis in primary kidney cells was performed in two
independent experiments.
2.6. Spectrophotometric Measurement of Anti-Oxidant Capacity of Platinum Compounds
The influence of PN149 on the rates of the reaction of fluorescein with free radicals
generated by the azo initiator 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH)
was studied according to [35] in phosphate buffer (PB, 50 mM, pH 7.4) by measuring
the decay of the probe at 494 nm with absorption spectrophotometer Specord UV–Vis
equipped with a thermostated cell maintained at 37 ◦C. The reaction was started by the
addition of AAPH to a preheated solution of fluorescein or fluorescein plus cisplatin or
PN149 in PB. The lag phase of the reaction means no changes in the optical density of
the reaction mixture. AAPH and fluorescein were purchased from Sigma-Aldrich, JM216
[e-ammine-d-(cyclohexylamine)-a,f -bis(acetato)-b,c-dichloroplatinum(IV)] was obtained as
described in [36].
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3. Results and Discussion
3.1. Experimental Models for In Vitro Nephrotoxicity Studies
With respect to nephrotoxicity investigations, choosing the right experimental model is
a challenging task. Potential new drugs often fail in clinical phase 1 and 2 safety assessments
due to nephrotoxicity that was not detected in previous preclinical studies. Many in vitro
as well as in vivo models proved to be unsuitable or unreliable to detect whether a drug
has the potential to be nephrotoxic to humans [37]. Membrane transporters, which play
a critical role in the impact of drugs and chemical compounds on kidney cells, are often
differently expressed in animal kidneys compared to the human kidney [38]. Therefore,
animal models should be used with caution for nephrotoxicity studies. Patient-derived
primary cells would be an ideal choice as they reflect the in vivo situation in the human
body. However, their availability is limited, inter-donor variability is high and primary
cells de-differentiate during passaging, resulting in reduced expression levels of some
membrane transporters and enzymes [39]. The use of permanent cell lines established
from human kidney cells would allow us to circumvent these limitations. One cell line,
which has been frequently used for nephrotoxicity studies over the years, is the human
embryonic kidney 293 (HEK293) cell line. However, it turned out that HEK293 might not
be of renal epithelial origin but is related to neuronal cells [40]. Another cell line frequently
used for nephrotoxicity studies is HK-2, an immortalized cell line of proximal tubule
origin. However, HK-2 cells have some drawbacks, as they retained only limited proximal
tubule functions, with only low expression levels of transporters of the solute carrier (SLC)
family, which are responsible for cisplatin uptake into proximal tubule cells [41–43]. More
recent kidney cell culture models, which retained their proximal tubule characteristics and
functionalities in vitro, are the cell lines RPTEC/TERT1 and ciPTEC [31,44]. RPTEC/TERT1
is derived from proximal tubule cells that were infected with a vector containing hTERT
cDNA [44]. The ciPTEC cell line was established by Wilmer and colleagues by infecting
primary renal cells with vectors containing the temperature-sensitive mutant of SV40
large T antigen (SV40T) and the catalytic subunit of human telomerase (hTERT) [31].
In this conditionally immortalized proximal tubule cell line, proliferation is maintained
at the permissive low temperature of 33 ◦C, while cells transferred to 37 ◦C grow into
tight confluent monolayers with functional membrane transporters involved in renal
reabsorption and excretion. ciPTECs were therefore used as a model for human renal
proximal tubular epithelial cells to study the activity of PN149 compared to the established
chemotherapeutic platinum drugs in human kidney cells.
3.2. Cytotoxic Potential of Platinum Compounds in ciPTEC
The cytotoxicity of PN149 in comparison to cisplatin, carboplatin and oxaliplatin was
determined by assessing cell viability through cell number. Differentiated ciPTECs were
incubated for 24 h with different concentrations of the respective platinum complexes and
cell count was measured after a post-cultivation period of 48 h. PN149 led to a strong
decrease in cell number, resulting in a reduction to less than 5% compared to the control
(Figure 2A). The pronounced cytotoxicity of PN149 is reflected by an IC50 value of 6 µM
(Table 1). A decrease in cell number was also observed for the other platinum compounds,
with cisplatin being slightly less cytotoxic than PN149, with a pronounced reduction in cell
number to less than 10% at 50 µM and an IC50 value of 13 µM. In contrast to these findings
in normal kidney cells, PN149 and cisplatin show comparable toxicity in cancerous cell
lines [28,29].
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Moderate cytotoxicity was observed for oxaliplatin (IC50 = 51 µM), while carboplatin
was only weakly cytotoxic and had to be applied at a concentration 10 times higher to
evoke a cytotoxic response (IC50 = 175) (Figure 2B, Table 1). Therefore, even though
all platinum compounds were cytotoxic in proximal tubule cells, the extent of toxicity
differed substantially. A cytotoxic impact on ciPTECs was also observed for cisplatin by
Nieskens and colleagues [45]. Using the MTT assay for toxicity studies, they calculated
a TC50 (≡ IC50) of 34 µM cisplatin in ciPTECs treated with cisplatin for 24 h. Secker and
colleagues, on the other hand, did not observe any toxicity after 24 h incubation with
cisplatin (10–100 µM) in the 2D cell culture model of RPTEC/TERT1 tubule cells using the
LDH assay [46]. However, by extending the post-cultivation time up to 11 days, a cytotoxic
impact was observed for the highest cisplatin concentration used (100 µM) [46]. The
discrepancy between the observations in ciPTEC versus RPTEC/TERT1 might be at least in
part due to the different assays used to investigate cisplatin toxicity. However, regardless
of the discrepancy in observations, our data revealed that oxaliplatin and carboplatin
were also toxic in an in vitro model of proximal tubule cells. These findings do not reflect
the clinical situation, as nephrotoxicity is not observed as an unwanted side effect for
chemotherapeutic treatment with carboplatin or oxaliplatin. Unfortunately, no comparable
studies about the effect of carboplatin and oxaliplatin in ciPTEC or RPTEC/TERT1 human
proximal tubule cells have been performed to date. Few studies investigated the impact of
carboplatin and oxaliplatin in comparison to cisplatin in renal cell lines. In the MDCK dog
kidney cell line, a strong toxic effect was observed for the three clinically approved platinum
compounds [47]. Similarly, high toxicity following treatment with the three compounds
was shown in the rat renal proximal tubular epithelial cell line NRK-52E [48]. In vivo
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studies, however, revealed renal damage induced by cisplatin, but not by carboplatin
and oxaliplatin [49], demonstrating again the challenges of nephrotoxicity studies. In the
present in vitro studies using a model system for human proximal tubule cells, the most
pronounced cytotoxicity was observed for the experimental compound PN149, which
one might consider as an indication of possible nephrotoxicity. However, as the cell
culture observations of carboplatin and oxaliplatin do not reflect the clinical situation, one
cannot rule out a different in vivo response of PN149 in the human kidney. Altogether,
the observations reflect the problem of performing nephrotoxicity studies using in vitro
models. Nevertheless, one could argue that investigating only acute toxicity is not sufficient
for analyzing the nephrotoxic potential of a drug. Furthermore, elucidating the mode of
action of different platinum compounds in normal kidney cells might help to design new
and improved platinum drugs. Therefore, further studies regarding intracellular platinum
accumulation and detailed gene profiling were carried out.
3.3. Intracellular Platinum Accumulation
The main targets of the toxic effects of cisplatin in the kidneys are epithelial cells
located in the S3 segment of the proximal tubule. The kidney is the major excretory organ
of cisplatin, hence a five times higher accumulation of the drug has been observed in
epithelial cells of the proximal tubule compared to blood plasma concentrations [50,51].
Furthermore, the activity of specific transporters in the membranes of epithelial cells,
especially of the solute carrier (SLC) family, is responsible for its high uptake in proximal
tubule epithelial cells (PTECs) [42,43]. Carboplatin and oxaliplatin, on the other hand, have
little or no nephrotoxic potential, which might be due to the observation that carboplatin
and oxaliplatin show little accumulation in nephron cells [52]. To compare the intracellular
accumulation of cisplatin, carboplatin and oxaliplatin in comparison to PN149 in kidney
tubule cells, ciPTECs were incubated for 2 h with 50 µM of either PN149, cisplatin or
oxaliplatin or 300 µM carboplatin, and the platinum amount was measured directly after
treatment by AAS. The chemotherapeutics cisplatin, oxaliplatin and carboplatin showed
comparable amounts of platinum accumulation, while for PN149 are about 20 times
higher platinum accumulation was observed (Table 1). The stronger cytotoxicity of PN149
compared to cisplatin, carboplatin and oxaliplatin might therefore be due to, at least in part,
higher intracellular platinum accumulation. For PNCs, a relationship between platinum
accumulation and DNA platination was established, and increased DNA platination was
correlated with increased toxicity [28].
High accumulation upon PN149 might be explained by the strong lipophilicity of
the compound, as a correlation between the length of the axial ligand, which increases
lipophilicity, and cellular accumulation has been observed for various PNCs [28]. It is
discussed that, due to high lipophilicity, PNCs are mainly taken up by passive diffusion
through the lipid bilayer, while active transport mechanisms by membrane transporters
seem to play a minor role. As a consequence, the activity of specific transporters in the
membranes of the proximal tubule cells would not affect the influx of PN149. For cisplatin,
on the other hand, the involvement of membrane transporters in renal uptake and efflux
has been shown. The organic cation transporter 2 (OCT2), which is part of the SLC family,
is highly expressed in the basolateral membrane of PTECs and appears to be a major key
player in the uptake of cisplatin in PTECs. A number of studies have shown a correlation
between OCT2-mediated uptake and cisplatin-induced nephrotoxicity [42,53,54]. For ox-
aliplatin, uptake via OCT2 has also been observed, while carboplatin has no affinity to
this transporter, which explains the lack of nephrotoxicity during carboplatin chemother-
apy [49,55]. Oxaliplatin is taken up by OCT2 in kidney tubule cells, but also has no
nephrotoxic potential. This might be explained by the high efflux of oxaliplatin out of
tubule cells compared to the efflux of cisplatin. The SLC family members multidrug and
toxin extrusion 1 and 2-K (MATE1/2-K) are implicated in the efflux of substances out of
kidney cells [56]. Cisplatin shows no affinity for MATE2-K and has only low affinity for
MATE1, whereas oxaliplatin represents a substrate for both MATE1 and MATE2-K, which
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will result in the efflux of oxaliplatin out of tubule cells and hence might explain the lack of
nephrotoxicity [56]. Based on the different affinities of the platinum complexes towards
the membrane transporters, one would expect differences in platinum levels following
treatment with the three platinum drugs, which, however, was not the case (Table 1). In a
comparable study, Yonezawa and colleagues analyzed the intracellular platinum accumu-
lation following incubation with the three platinum-based compounds in HEK293 cells.
Using 500 µM of each compound, they observed a comparable intracellular accumulation
of cisplatin and oxaliplatin, while the intracellular accumulation of carboplatin was only
a fraction of that [56]. In A498 kidney cancer cells, we also observed that at equimolar
concentrations carboplatin showed substantially lower platinum accumulation than ox-
aliplatin and cisplatin, while equitoxic concentrations led to an accumulation similar to
that of cisplatin [57]. However, in vivo animal studies revealed a considerably higher
accumulation in rat kidneys following cisplatin treatment as compared to carboplatin or
oxaliplatin [49]. Altogether, the data indicate that simple cell culture models obviously do
not reflect the situation in the kidney adequately and therefore are not the best suited model
to study the complex mechanisms of nephrotoxicity. Ludwig and colleagues investigated
the influence of different cell culture models on the toxicity of cisplatin, carboplatin and
oxaliplatin [58]. They cultivated the C7 clone of the canine kidney MDCK cell line in a
Transwell® system, which enables the differentiation of the basolateral and luminal side of
epithelia, to investigate the influence of the side of application for platinum toxicity. Their
results revealed that toxic effects of platinum complexes on renal epithelial cells depend
on both the platinum complex and the side of application. Carboplatin and oxaliplatin
were also toxic in kidney cells, as shown by the activation of caspase-3, but to a lesser
extent than cisplatin. The strongest toxic effect was observed for cisplatin when it was
applied on the basolateral side [58]. Altogether, the data again highlight the complexity
of studying nephrotoxicity. Transport in renal proximal tubule cells is the most essential
function in the kidney and therefore different membrane transporters are expressed in the
basolateral and luminal membrane to guarantee the transcellular transport of endogenous
compounds and xenobiotics. Hence, this function must be ensured in a cell culture study
to investigate the nephrotoxic potential of a potential new drug. The gene expression of
membrane transporters increases with the complexity of the cell culture model [59,60],
and it is therefore recommended to test the nephrotoxic potential of a potential new drug
in a more complex cell culture model. Nevertheless, to analyze the intracellular effects
of platinum-based compounds in normal renal cells, the impact on cellular signalling
pathways involved in the maintenance of genomic stability was analyzed in the cell culture
model of ciPTEC.
3.4. Gene Expression Profiling
Gene expression profiles were generated to identify the cellular response of the ex-
perimental compound PN149 in comparison to the established chemotherapeutic drugs
cisplatin, carboplatin and oxaliplatin in kidney proximal tubule cells. It is well understood
that, due to its relatively high reactivity, cisplatin induces different cellular signaling path-
ways, which will ultimately lead to cell death [13]. Important signaling pathways that
are implicated in cisplatin-induced nephrotoxicity are, among others, the MAPK signal-
ing cascade as well as the p53 signaling cascade [61]. Detailed studies on the effect of
platinum-based chemotherapeutics on renal cells and the involved signaling pathways,
however, are rare. Comparative analysis of the expression of genes related to cellular
transport, DNA repair and apoptosis was carried out in PTECs of the rat [48], while for
human PTECs only data obtained for cisplatin are available [62]. We therefore extended
these studies in ciPTECs. ciPTECs were treated for 24 h with different concentrations of
the respective platinum compound, followed by quantitative high-throughput RT-qPCR to
generate gene expression profiles of selected genes. The analyzed genes were clustered into
groups of transcription factors, DNA damage response (DDR) and repair, cell cycle control,
(oxidative) stress response and apoptosis. Relative gene expressions were calculated by
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normalizing the treated samples to the untreated control and are expressed as log2 values.
The gene expression profiles are presented in a heatmap in Figure 3.
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3.4.1. Impact of Platinum Complexes n Genes Coding for Transcription Factors
Treatment with 20 µM PN149 led to widespread gene repression of genes related to
transcription factors (Figure 3).
Cisplatin at the highest concentration of 50 µM also resulted in a strong down-
regulation of gene transcripts. Carboplatin, on the other hand, showed no general down-
regulation, while for oxaliplatin widespread gene repression was restricted to the high-
est concentration used (150 µM). Widespread gene down-regulation might indicate pro-
nounced cytotoxicity and hence impaired survival, which is supported by the findings
regarding the cytotoxicity of the platinum compounds (Figure 2A) and was also confirmed
by visual observation of the cells. Under viable conditions, all four platinum compounds
led to a weak induction of JUN and KEAP1. JUN encodes the JUN rotein subunit of the
transcription factor AP-1, which is implicated in cell proliferati , cell differentiation and
apoptosis [63]. Increased JUN expression therefore indicates an activation of AP-1 by the
platinum omplexes. KEAP1, as part of the KEAP1–Nrf2–ARE pathway of anti-oxidant
gene regulation, might s rve as n indicator for the induction of oxidative str ss [64].
Positive modulations of the proliferation-associated JUN and KEAP1 suggest the activation
of cell cycle progression and induction of an oxidative stress response following expo-
sure to PN149 and the chemotherapeutics in normal human kidney cells. However, a
strong repression of MAP3K5 coding for MAPKKK5/Ask1 kinase, which is part of the
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mitogen-activated protein kinase (MAPK) pathway, was also observed. MAPK pathways
consist of cascades of serine/threonine kinases, which control cellular homeostasis, cell
differentiation, cell proliferation and survival [65]. This observation would rather suggest
an inhibitory effect on cell cycle progression by the platinum compounds. NFKB2 was
transcriptionally slightly enhanced by cisplatin and oxaliplatin, while repressed transcript
levels were observed for PN149 and carboplatin. NFKB2 encodes a precursor subunit of
the transcription factor NFκB [66], which controls a number of cellular processes, among
them angiogenesis, cell proliferation and inflammatory activity [67]. As inflammation is
one of possible causes contributing to nephrotoxicity, the observations indicate a possible
inflammatory response in kidney proximal tubule epithelia by cisplatin and oxaliplatin,
but a lack of it following treatment with carboplatin and PN149.
3.4.2. Impact of Platinum Complexes on Genes Related to Oxidative Stress Response
and Inflammation
The impact of the platinum compounds on the expression of oxidative stress response
genes is summarized in Figure 3. The ROS-inducible HMOX1 gene was strongly induced
by PN149 and carboplatin, while slightly lesser effects were observed in the case of cis-
platin and oxaliplatin. The HMOX1 protein has a protective effect against oxidants, hence
the lack of HMOX1 in HMOX1 KO mice resulted in increased cisplatin-induced nephro-
toxicity [68]. PN149 led to a strong concentration-dependent increase in the heat-shock
sensitive HSPA1A, which was, however, restricted to cytotoxic conditions, whereas a less
pronounced effect was observed for the other three platinum compounds. The transcription
of HMOX1 and HSPA1A is mediated via different redox-sensitive transcription factors such
as Nrf2 and NFκB, which makes HMOX1 and HSPA1A marker genes for ROS generation.
Therefore, gene expression analysis indicates ROS production by PN149 and, to a lesser
extent, by the three chemotherapeutic platinum drugs in normal proximal tubule epithelia
of humans. With regard to genes associated with the anti-oxidant defense system, a signifi-
cant up-regulation was observed for GCLC and TXNRD1, which code for anti-oxidative
enzymes, while weak gene modulation was observed for SOD1, TXN1, PRDX1, TFRC,
and GPX, which are all related to the glutathione and thioredoxin system. On the other
hand, strong down-regulation was observed for CAT and SOD2 in the case of all four
compounds, suggesting the depletion of anti-oxidant enzymes. Experiments in rodents
showing significantly reduced renal activity of superoxide dismutase and catalase follow-
ing cisplatin treatment support the gene expression analysis on the functional level [69].
On the other hand, Wilmes and co-authors observed an increased expression of CAT in
RPTEC kidney cells, while SOD2 transcript levels were also reduced [62], which is in line
with observations of reduced amounts of SOD2-encoded MNSOD protein in cisplatin-
induced in vivo nephrotoxicity [70]. Altogether, the gene expression analysis revealed the
induction of genes associated with the anti-oxidant defense at the transcriptional level
for all compounds, suggesting an oxidative stress response in normal proximal tubule
cells due to ROS formation. ROS are discussed as one factor contributing to cisplatin-
induced nephrotoxicity [71]. ROS formation following cisplatin treatment was observed
only in epithelial cells of the S3 segment of the proximal tubule, which is the main place of
cisplatin-induced nephrotoxicity, but not in cells of the medullary collecting tube, which
are not a target for cisplatin nephrotoxicity [72]. Furthermore, it has been demonstrated
that anti-oxidants reduce cisplatin-induced nephrotoxicity in animal models [73]. An
anti-oxidative potential is also attributed to nitroxyl radicals, which mimic the activity
of superoxide dismutase and/or stoichiometrically react with ROS [74,75]. PNCs were
therefore designed by the addition of an aminonitroxyl group to platinum, with the aim to
develop a platinum compound with a potential anti-oxidant property and hence reduced
dose-limiting nephrotoxicity. However, based on the toxicity data of the present study,
it is difficult to conclude on an anti-oxidative and hence protective potential by PN149.
Experiments were therefore carried out to investigate for a possible anti-oxidant capac-
ity of PN149 in comparison to cisplatin. The method to assess anti-oxidant capacity is
based on the ability of anti-oxidants to scavenge peroxyl radicals, RO2•, generated by the
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azo-initiator AAPH and thus to inhibit the consumption of fluorescein used as a probe.
Fluorescein consumption is easily monitored spectrophotometrically at 494 nm [35]. PN149
effectively inhibited the consumption of fluorescein and produced a clear lag phase directly
proportional to the concentration of the complex (Figure 4, curves 3–5). Cisplatin was
also not inert in this investigation, but only slightly slowed down the consumption of
fluorescein (curve 2). This weak effect of cisplatin probably explains the behavior of curves
3–5 after ~20 min of reaction. By this time, the nitroxyl radical of PN149 is consumed and
the course of curves 3–5 differs only insignificantly. Interestingly, the kinetics of fluorescein
consumption in the presence of the PtIV complex JM216 (10 M) practically coincided with
curve 2 for cisplatin (data not shown), which might indicate that the PtII/PtIV metals do not
participate in the reaction and some part of RO2• radicals react with the amino groups of
the platinum complexes. Altogether, PN149 showed an oxygen radical absorbance capacity
in a simple test model. However, this does not necessarily indicate such an activity in a
complex system such as the cell, as gene expression analysis showed the modulation of
genes related to ROS production and oxidative stress response by PN149, and PN149 was
highly cytotoxic in ciPTECs.
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peroxyl radicals g nerated from APH (50 mM) in phosphate bu fer (50 , t 37 ◦ . The
cons tio of fluorescei as follo e by visible absorptio at 494 n in the absence (1) and
presence of cisplatin (2, 10 µM) and PN149 (3, 10 µM), (4, 25 µM), and (5, 50 µM).
Infla t r , T Fα and NFκB, have also been implicated
in the toxicity of cisplatin to kidney cells [4,12–16]. Possible inflammatory ac ivit by
the platinum compounds was investigated via th expression of IL-8, ich a
arker for inflam ation. The treatment of ciPTECs with cisplat n and oxaliplatin increased
transcript levels of IL-8, while PN149 and carboplatin led to repressed gene xpr ssion
(Figure 5), sugg sting a pro-infl mmatory response in human renal proximal tubule ep-
ithelia by cisplatin and oxaliplatin, but not y PN149 and carboplatin. As inflammatory
processes have been linked to ROS-induced oxi ative stress [76], h lack of an inflamm -
tory response by PN149 might be an indication of the xygen radical absorbance capacity
of PN149 in a cellular system. In additio , the expression of inflammatory genes such as
IL-1, IL-6 and IL-8 is controlled, among other factors, by NFκB [67], which is in line with
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the increased expression of the NFκB subunit gene NFKB2 upon treatment with cisplatin
and oxaliplatin (Figure 3).
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cell cycle [77]. Howev r, upon genotoxic stress and DNA damage, the DDR system in
kidney cells is activated, inducing entry into the cell cycle [78]. E2F1, CCND1 and MYC are
mplicated in he G1-to-S transition [79–81]; th r fo , gene expres ion analysis indicates
progression from the semi-permanent G0-phase into the cell cycle in pl tinum-damaged
ciPTECs. Howev r, inc a ed expression of CDKN1A coding for the cyclin-dep ndent
kinase inhibitor p21 wo ld rath r suggest cell cycle arrest following platinum tr atment.
The activation of cell cycle arrest and DNA repair will nable the cells to re ove da ag
from the DNA to make sure that the fidelity of the DNA is restored before entry into the
S- and M-phase. p21 is implicated in bot arrest at the G1-to-S transition a d inhibition
of the G2-to-M transition [82]. In tubular epithelial cells, p21-mediated blockade of the
G2-to-M transition in response to damage has been associated with nephrotoxicity and
chronic kidney disease [83].
Taken together, at viable concentrations PN149 and the chemotherapeutic platinum
drugs might lead to an entry into the cell cycle followed by the activation of cell cycle
checkpoints to ensure that DNA damage is repaired and DNA fidelity is intact before
further progressing through the cell cycle [84]. These results confirm previous studies
reporting the activation of cell cycle regulation by cisplatin in the rodent NRH-52E kidney
cell line and in vivo animal models of rats, demonstrated by enhanced expression of
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proliferation-related p21 on the gene and protein level, which was both dependent and
independent of p53 [62,85,86].
3.4.4. Impact of Platinum Complexes on Genes Related to DNA Damage Response/Repair
and Apoptosis
With regard to genes related to DNA damage response and repair, treatment with non-
toxic concentrations of the platinum compounds led to enhanced expression of GADD45A
and PCNA. GADD45A and PCNA are target genes of p53; therefore, enhanced transcript
levels indicate a p53-dependent DNA damage response following platinum treatment in
normal kidney tubule epithelial cells. Non-toxic concentrations of the platinum compounds
also led to increased expression of BRCA1/BRCA2 and RAD51, which are part of homolo-
gous recombination double strand break (DSB) repair. It is discussed that DSBs might arise
during the processing of DNA interstrand crosslinks (ICLs), which are induced by common
agents such as mechlorethamine and also cisplatin. However, no DSBs were detected
following cisplatin treatment [87]. On the other hand, γH2AX staining, which serves as a
marker for DSBs, was observed in various cancer cell lines [88]. One could envisage that
the processing of cisplatin-induced ICLs leads to the formation of ICL repair-associated
DSB-intermediates, which are targets of homologous recombinational DSB repair in normal
kidney tubule cells. BRCA1/BRCA2 and RAD51 proteins have been implicated in the repair
of ICLs [89], which is in line with observed increased transcript levels of BRCA1/BRCA2
and RAD51 following treatment with PN149 and the chemotherapeutic drugs, indicating
ICL repair in normal kidney epithelial cells. Furthermore, the transcription of MSH2, POLB
and POLD1, which are implicated in mismatch repair, base excision repair and nucleotide
excision repair [90–92], respectively, was increased by PN149 and the chemotherapeutic
drugs in ciPTECs, indicating the activation of the DDR system in normal epithelial kidney
cells treated with platinum compounds under viable conditions. Using cytotoxic concentra-
tions of PN149, cisplatin and oxaliplatin, widespread gene repression was observed, while
carboplatin did not lead to a general repression of transcript levels (Figure 3).
In vivo studies suggested that cisplatin leads to nephrotoxicity via the induction of
apoptosis and, to a lesser extent, necrosis in proximal tubule epithelia [93]. Cisplatin-
induced apoptosis may be triggered through the extrinsic death receptor pathway or
the intrinsic mitochondrial pathway [94]. ciPTECs treated with the respective platinum
compounds showed modulation of pro- and anti-apoptotic genes (Figure 3). The gene
expression level of the anti-apoptotic gene BCL2 was slightly induced, which would
indicate the prevention of apoptosis upon platinum drug treatment in proximal tubule cells.
On the other hand, genes affecting both the extrinsic and the intrinsic apoptotic pathway
were also induced by the platinum drugs. A strong concentration-dependent increase in
the gene expression of the pro-apoptotic gene PMAIP1, encoding the protein Noxa, was
observed following treatment with cisplatin, carboplatin and oxaliplatin. PN149-induced
PMAIP1 levels, on the other hand, peaked at 20 µM, followed by a decrease at 50 µM.
Under these conditions, strong cytotoxicity was observed 48 h post-treatment (Figure 2A).
Platinum treatment also increased transcript levels of the pro-apoptotic genes BAX, BBC3
and TNFRSF10B, however, to a lesser extent and restricted to viable concentrations. With
respect to pro-apoptotic signaling, effects were observed for both the intrinsic pathway
(PMAIP1, BAX, BBC3) and extrinsic pathway (TNFRSF10B), suggesting that PN149 and
the chemotherapeutic drugs induce apoptosis in proximal tubule cells, which is executed
via the intrinsic and extrinsic pathway. Furthermore, BAX, PMAIP1 and TNFRSF10B are
transcriptionally regulated by p53 [95], which suggests a critical role for p53 in platinum-
induced apoptosis in proximal tubule cells. With regard to cisplatin, carboplatin and
oxaliplatin, the induction of apoptosis in kidney cells has been confirmed on the functional
level. Jiang and co-authors observed the activation of p53, followed by strong expression
of BBC3-encoded PUMA and activation of BAX, leading to apoptosis in RPTC normal rat
kidney proximal tubular cells [96]. Likewise, Krüger and co-authors observed an increased
expression of the apoptotic gene BAX following treatment with cisplatin, carboplatin and
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oxaliplatin in rat NRK-52E kidney cells, which was accompanied by the activation of
caspases 3 and 7 on the functional level [48].
Taken together, our data indicate an induction of the DDR system at the transcriptional
level by PN149 and the established platinum chemotherapeutics in normal human tubule
kidney cells. At viable concentrations, repair pathways are activated for cells to cope with
the damage. Severe damage, however, will trigger apoptotic cell death via the extrinsic
and intrinsic apoptotic cascade and eliminate the injured tubular epithelial cells.
3.5. Comparison of Gene Expression Profiles of Cisplatin in ciPTECs vs. Normal Renal
Tissue Cells
The observations above illustrate the problems one encounters when performing
in vitro nephrotoxicity studies. ciPTECs, which retained characteristics of proximal tubule
epithelia, were used as a permanent cell line for the current investigations. To validate
the findings obtained with ciPTECs in a model that resembles the in vivo situation more
closely, primary cells derived from human kidneys were used. The treatment of primary
kidney cells with 20 µM cisplatin for 24 h resulted in platinum levels of 25 ng Pt/106 cells
as compared to 17 ng Pt/106 cells, which were observed in ciPTECs (Table 2). Possibly,
differences in expression levels of membrane transporters can account for the higher
platinum levels in primary kidney tubule cells, as permanent cell lines often show reduced
or missing expression of membrane transporters.
Table 2. Platinum accumulation in ciPTECs and primary kidney cells following incubation with
50 µM cisplatin for 2 h. Shown are mean values from at least three independent determinations ±
standard deviation.
Cellular Model ng Pt/106 Cells
ciPTEC 17 ± 5
Primary kidney cells 25 ± 5
Gene expression analysis was performed to establish expression profiles associated
with cisplatin nephrotoxicity, and gene clusters were arranged in network diagrams to
compare the data of the primary kidney cells with ciPTECs (Figure 6).
With regard to genes related to transcription factors, DNA damage response, cell cycle
control, (oxidative) stress response and apoptosis, a comparable impact on gene expression
was observed in both cellular models. Overall, expression levels were more pronounced
in ciPTECs, suggesting a more sensitive reaction of the permanent cell line to cisplatin.
With regard to genes related to DNA repair, however, a profound difference between the
two model systems was observed. While increased expression of several repair-related
genes was observed in cisplatin-treated ciPTECs, reduced transcript levels were seen in
normal tissue (Figure 6). This might be due to the degree of differentiation of the cells.
The down-regulation of repair genes and hence attenuated global genome DNA repair is
observed in terminally differentiated cells, which is explained by the reduced necessity to
remove DNA lesions from the non-essential mass of the DNA [97]. In line with the gene
expression analysis of DNA repair genes, a reduced repair capacity has been observed in
kidney tissue affected by AKI, which often occurs as a result of cisplatin chemotherapeutic
treatment [98].
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In general, primary renal tissue is best suited for investigation regarding the kidney,
as it offers the closest reflection of the in vivo situation. However, a number of limitations
must be taken into account. Inter-individual variations of tissue donors need to be con-
sidered for the interpretation of experimental results. Furthermore, cells derived directly
from the human kidney are limited. Therefore, the permanent cell line ciPTEC offers a
good alternative for experimental studies regarding the impact of compounds on cellular
processes in kidney cells. However, simple in vitro cell culture models are not best suited
to investigate the complex mechanisms of nephrotoxicity. In the present study, all four
platinum compounds were toxic in ciPTECs and evoked a similar cellular response. This,
however, does not reflect the clinical situation, where carboplatin and oxaliplatin show
little or no toxicity in proximal tubule epithelia in cancer patients. Caution should therefore
be used to extrapolate the in vitro toxicity data of the experimental compound PN149 to an
in vivo situation, and definite conclusions about the nephrotoxic potential of PN149 should
not be drawn on the basis of the present study. As the kidney is a highly complex organ,
whose function relies on transport processes, a more complex model, such as Kidney-on-a-
chip, which enables more realistic transport processes in kidney cells, might offer a better
suited system for complex nephrotoxicity studies [99]. Alternatively, tubule suspensions
or proximal tubular-like cells derived from human-induced pluripotent stem cells might
be used as a proximal tubular cell model [100]. Nonetheless, the information gained in
the current study about the impact of the platinum drugs on pathways related to genomic
stability might help for the design of new platinum drugs that are safer for patients.
4. Conclusions
Cisplatin is one of the major drugs used for cancer treatment. Unfortunately, its use
is restricted by toxic side effects, especially dose-limiting nephrotoxicity. Therefore, new
platinum analogues are designed, aimed at reducing or removing nephrotoxicity. The
mode of action of the experimental platinum compound PN149 was elucidated on the
transcriptional level in normal human kidney tubule epithelial cells in comparison to the
clinically approved platinum chemotherapeutics cisplatin, carboplatin and oxaliplatin.
The expression of genes related to genomic stability revealed an impact of PN149 on
the oxidative stress response, DNA damage response/repair, cell cycle regulation and
apoptosis, similar to that observed for the chemotherapeutic drugs. However, no pro-
inflammatory response, which was shown to be of major importance for cisplatin-induced
nephrotoxicity, was observed in PN149-treated ciPTECs, which might indicate the reduced
nephrotoxic potential of PN149. PN149 was highly cytotoxic to the human proximal
tubule ciPTEC cell line, accompanied by high levels of intracellular platinum accumulation.
Intracellular platinum levels were similar for cisplatin, carboplatin and oxaliplatin, which
does not reflect clinical observations in cancer-treated patients. The present study highlights
the problems of performing nephrotoxicity studies in vitro and stresses that caution has to
be taken when extrapolating data from an in vitro model system to the in vivo situation.
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